This excerpt taken from the VRTX 8-K filed Jul 31, 2008.
Additional Pipeline Advancements
· In the second quarter, Vertex initiated dosing in a Phase 1a clinical trial of VX-509, a novel Janus kinase 3 (JAK3) inhibitor, being investigated for the treatment of multiple immune-mediated inflammatory diseases.
· In the second quarter, Vertexs collaborator Merck initiated a Phase 1 clinical trial of the Aurora kinase inhibitor MK-5108 (VX-689) in patients with advanced and/or refractory tumors. In addition, Merck has terminated development of the Aurora kinase inhibitor MK-0457 (VX-680) for the treatment of cancer following the previously announced suspension of clinical trial enrollment for this compound.